GetTopicDetailResponse(id=c62a268958c, topicName=依托泊苷, introduction=依托泊苷, content=null, image=null, comments=2, allHits=1843, url=https://h5.medsci.cn/topic?id=26895, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=1163, tagList=[TagDto(tagId=1163, tagName=依托泊苷)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2264398, encodeId=56d52264398b4, content=<a href='/topic/show?id=0a9e922085f' target=_blank style='color:#2F92EE;'>#貝伐珠單抗#</a> <a href='/topic/show?id=c62a268958c' target=_blank style='color:#2F92EE;'>#依托泊苷#</a> <a href='/topic/show?id=9dc636545a4' target=_blank style='color:#2F92EE;'>#卡鉑#</a> <a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#廣泛期小細(xì)胞肺癌#</a> <a href='/topic/show?id=6bf49e844e9' target=_blank style='color:#2F92EE;'>#阿替利珠單抗#</a>, objectTitle=JITC | GOIRC-01-2019 CeLEBrATE研究：卡鉑、依托泊苷、阿替利珠單抗聯(lián)合貝伐珠單抗一線(xiàn)治療廣泛期小細(xì)胞肺癌的療效與安全性, objectType=article, longId=875440, objectId=8cfa8e54404c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250122/1737525065730_8538692.png, objectUrl=/article/show_article.do?id=8cfa8e54404c, replyNumber=0, likeNumber=38, createdTime=2025-05-10, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8cfa8e54404c, moduleTitle=JITC | GOIRC-01-2019 CeLEBrATE研究：卡鉑、依托泊苷、阿替利珠單抗聯(lián)合貝伐珠單抗一線(xiàn)治療廣泛期小細(xì)胞肺癌的療效與安全性, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=8cfa8e54404c)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2241985, encodeId=e690224198526, content=廣泛期<a href='/topic/show?id=5e2e4e08988' target=_blank style='color:#2F92EE;'>#小細(xì)胞肺癌#</a>的標(biāo)準(zhǔn)一線(xiàn)治療是鉑類(lèi)與<a href='/topic/show?id=c62a268958c' target=_blank style='color:#2F92EE;'>#依托泊苷#</a>，聯(lián)合PD-L1抑制劑。二線(xiàn)治療則是<a href='/topic/show?id=1c855620260' target=_blank style='color:#2F92EE;'>#拓?fù)涮婵?</a>和<a href='/topic/show?id=aef712222ee9' target=_blank style='color:#2F92EE;'>#魯比奈克汀#</a>。二線(xiàn)治療的中位無(wú)進(jìn)展生存時(shí)間為3.5個(gè)月。
<a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗體偶聯(lián)藥物#</a><a href='/topic/show?id=174e1222167d' target=_blank style='color:#2F92EE;'>#ABBV-011#</a>是針對(duì)SEZ6的抗體偶聯(lián)藥，總體的治療緩解率為25%，也就是25%的患者腫瘤病灶縮小超過(guò)30%，中位緩解持續(xù)時(shí)間為4.2個(gè)月，中位無(wú)進(jìn)展生存時(shí)間為3.5個(gè)月。
從這里來(lái)看ABBV-011仍然沒(méi)有什么突破性進(jìn)展，后續(xù)2，3期臨床還能否達(dá)到這樣的效果，還不好說(shuō)。
總的一句話(huà)，小細(xì)胞肺癌，真的太難太難。, objectTitle=治療小細(xì)胞肺癌的抗體偶聯(lián)藥ABBV-011，首次人體臨床試驗(yàn)結(jié)果公布了！, objectType=article, longId=852947, objectId=c38885294edf, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240709/1720491961813_92910.png, objectUrl=/article/show_article.do?id=c38885294edf, replyNumber=0, likeNumber=62, createdTime=2024-12-12, rootId=0, userName=俠膽醫(yī)心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=c38885294edf, moduleTitle=治療小細(xì)胞肺癌的抗體偶聯(lián)藥ABBV-011，首次人體臨床試驗(yàn)結(jié)果公布了！, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=c38885294edf)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2202057, encodeId=aa1d220205ecb, content=<a href='/topic/show?id=c62a268958c' target=_blank style='color:#2F92EE;'>#依托泊苷#</a> <a href='/topic/show?id=52cb52309d9' target=_blank style='color:#2F92EE;'>#急性早幼粒細(xì)胞白血病#</a> <a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, objectTitle=【BJH】全口服誘導(dǎo)方案治療高危APL的回顧性研究：口服依托泊苷替代靜脈化療, objectType=article, longId=824532, objectId=1f3e8245326a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-in-his-practice-with-a-digital-tablet-UWZKVBN.jpg, objectUrl=/article/show_article.do?id=1f3e8245326a, replyNumber=0, likeNumber=125, createdTime=2024-05-06, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=1f3e8245326a, moduleTitle=【BJH】全口服誘導(dǎo)方案治療高危APL的回顧性研究：口服依托泊苷替代靜脈化療, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=1f3e8245326a)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1009213, encodeId=2350100921380, content=<a href='/topic/show?id=c62a268958c' target=_blank style='color:#2F92EE;'>#依托泊苷#</a>樂(lè)伐替尼與依托泊苷和異環(huán)磷酰胺的聯(lián)合方案在復(fù)發(fā)性/難治性骨肉瘤患者中展現(xiàn)出了令人期待的抗腫瘤活性，而且無(wú)新增安全性問(wèn)題。, objectTitle=依托泊苷, objectType=topic, longId=26895, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=0, createdTime=2021-08-18, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話(huà)題小助手
2020-05-29
前往app查看評(píng)論內(nèi)容
廣泛期#小細(xì)胞肺癌#的標(biāo)準(zhǔn)一線(xiàn)治療是鉑類(lèi)與#依托泊苷#，聯(lián)合PD-L1抑制劑。二線(xiàn)治療則是#拓?fù)涮婵?和#魯比奈克汀#。二線(xiàn)治療的中位無(wú)進(jìn)展生存時(shí)間為3.5個(gè)月。
#抗體偶聯(lián)藥物##ABBV-011#是針對(duì)SEZ6的抗體偶聯(lián)藥，總體的治療緩解率為25%，也就是25%的患者腫瘤病灶縮小超過(guò)30%，中位緩解持續(xù)時(shí)間為4.2個(gè)月，中位無(wú)進(jìn)展生存時(shí)間為3.5個(gè)月。
從這里來(lái)看ABBV-011仍然沒(méi)有什么突破性進(jìn)展，后續(xù)2，3期臨床還能否達(dá)到這樣的效果，還不好說(shuō)。
總的一句話(huà)，小細(xì)胞肺癌，真的太難太難。
